“Pharmacogenetics of Cancer” - Cancer Drug Resistance special issue

References

[1] Roden DM,Relling MV,Mensah GA.Pharmacogenomics..Lancet2019;394:521-32 PMCID:PMC6707519

[2] Mini E.Pharmacogenetics: implementing personalized medicine..Clin Cases Miner Bone Metab2009;6:17-24 PMCID:PMC2781211

[3] Wake DT,Dunnenberger HM.Pharmacogenomics: prescribing precisely..Med Clin North Am2019;103:977-90

[4] Levitzki A.My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer..Proc Natl Acad Sci U S A2019;116:11579-86 PMCID:PMC6575164

[5] Church D,Domingo E,Palles C.‘Toxgnostics’: an unmet need in cancer medicine..Nat Rev Cancer2014;14:440-5

[6] Holohan C,Longley DB.Cancer drug resistance: an evolving paradigm..Nat Rev Cancer2013;13:714-26

[7] FDA. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). Available from: https://www.fda.gov/media/119249/download [Last accessed on 12 Feb 2020]

[8] EMA. Concept paper on predictive biomarker-based assay development in the context of drug development and lifecycle. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-predictive-biomarker-based-assay-development-context-drug-development-lifecycle_en.pdf [Last accessed on 12 Feb 2020]

[9] PharmGKB website. Available from: https://www.pharmgkb.org [Last accessed on 12 Feb 2020]

[10] Kaehler M.Germline variants in cancer therapy..Cancer Drug Resist2019;2:18-30

[11] Olivera G,José Herrero M,Gargallo P.Pharmacogenetics implementation in the clinics: information and guidelines for germline variants..Cancer Drug Resist2019;2:53-68

[12] Crisafulli C,Calabrò M,Alberti S.Pharmacogenetic and pharmacogenomic discovery strategies..Cancer Drug Resist2019;2:225-41

[13] Tarantino P,Morganti S,Viale G.Opportunities and challenges of implementing pharmacogenomics in cancer drug development..Cancer Drug Resist2019;2:43-52

[14] Hierro C,Martin-Liberal J,Garralda E.Agnostic-histology approval of new drugs in oncology: are we already there?.Clin Cancer Res2019;25:3210-19

[15] Renfro LA,Mandrekar SJ.Precision oncology: a new era of cancer clinical trials..Cancer Lett2017;387:121-6 PMCID:PMC5023449

[16] Bailey MH,Porta-Pardo E,Bertrand D.Comprehensive characterization of cancer driver genes and mutations..Cell2018;173:371-85.e18 PMCID:PMC6029450

[17] De Mattia E,Dalle Fratte C,Toffoli G.The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines..Cancer Drug Resist2019;2:116-30

[18] CPIC^® Guideline for Fluoropyrimidines and DPYD November 2018 & January 2020 Updates. Available from: https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/ [Last accessed on 12 Feb 2020]

[19] Franca R,Pagarin S,Lucafò M.Pharmacogenetics of thiopurines..Cancer Drug Resist2019;2:256-70

[20] Clinical pharmacogenetics implementation consortium guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update (November 2018). Available from: https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/ [Last accessed on 12 Feb 2020]

[21] Abaji R.Pharmacogenetics of asparaginase in acute lymphoblastic leukemia..Cancer Drug Resist2019;2:242-55

[22] Shek D,Ahlenstiel G.Pharmacogenetics of anticancer monoclonal antibodies..Cancer Drug Resist2019;2:69-81

[23] Murthy P.PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues..Cancer Drug Resist2019;2:665-79

[24] Kumar S,Gupta S.Emerging targets in cancer drug resistance..Cancer Drug Resist2019;2:161-77

[25] Belizario JE.Insights into breast cancer phenotying through molecular omics approaches and therapy response..Cancer Drug Resist2019;2:527-38

[26] Ravegnini G,Angelini S.Somatic pharmacogenomics of gastrointestinal stromal tumor..Cancer Drug Resist2019;2:107-15

[27] Alonso-Peña M,Sanchon-Sanchez P,Espinosa-Escudero R.Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma..Cancer Drug Resist2019;2:680-709